Characterizing Health Associated Risks, and Your Baseline Disease In SARS-COV-2 (CHARYBDIS)
=============

<img src="https://img.shields.io/badge/Study%20Status-Started-blue.svg" alt="Study Status: Started"> 

- Analytics use case(s): **Characterization**
- Study type: **Clinical Application**
- Tags: **OHDSI, Study-a-thon, COVID-19**
- Study lead: **Talita Duarte-Salles, Kristin Kostka, Albert Prats-Uribe**
- Study lead forums tag: **[[tduarte]](https://forums.ohdsi.org/u/tduarte)**, **[[krfeeney]](https://forums.ohdsi.org/u/krfeeney)**, **[[Albert_Prats]](https://forums.ohdsi.org/u/Albert_Prats)**
- Study start date: **April 21, 2020**
- Study end date: **Mid-June 2020**
- Protocol: **-**
- Publications: **-**
- Results explorer: **-**

Objectives: 1) Describe the baseline demographic, clinical characteristics, treatments and outcomes of interest among individuals tested for SARS-CoV-2 and/or diagnosed with COVID-19 overall and stratified by sex, age and specific comorbidities; 2) Describe characteristics and outcomes of hospitalized influenza patients between September 2017 and April 2018 compared to the COVID-19 population.
